SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-382267
Filing Date
2014-10-27
Accepted
2014-10-27 07:12:02
Documents
10
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d784389d10q.htm 10-Q 691718
2 EX-31.1 d784389dex311.htm EX-31.1 9165
3 EX-31.2 d784389dex312.htm EX-31.2 9190
4 EX-32.1 d784389dex321.htm EX-32.1 5530
  Complete submission text file 0001193125-14-382267.txt   6106609

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20140930.xml EX-101.INS 791656
6 XBRL TAXONOMY EXTENSION SCHEMA vnda-20140930.xsd EX-101.SCH 59828
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vnda-20140930_cal.xml EX-101.CAL 85708
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20140930_def.xml EX-101.DEF 392135
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20140930_lab.xml EX-101.LAB 425680
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20140930_pre.xml EX-101.PRE 467863
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 141173490
SIC: 2834 Pharmaceutical Preparations